Research and Clinical Trials
Research and Clinical Trials
Find research and clinical trial information for Pediatric Endocrinology at Penn State Children’s Hospital.
Call our office for more information
717-531-4751Research
Penn State Children’s Hospital stays on the leading edge of treatment for diabetes and hormone disorders in children by taking part in research and clinical trials.
Type 1 Diabetes Research
The TrialNet study is a natural history study of the development of Type 1 diabetes. The overall goal of this study is to perform baseline and repeat assessments over time of the metabolic and immunologic status of individuals at risk for Type 1 diabetes (T1D) to:
- Characterize their risk for developing T1D and identify subjects eligible for prevention trials.
- Describe the pathogenic evolution of T1D.
- Increase the understanding of the pathogenic factors involved in the development of T1D.
The study subjects include:
- First-degree relatives (parent, child, brother, sister) of T1D probands (the first individual in a family with Type 1 diabetes), ages 1 – 45 years.
- Second and third degree relatives (nieces, nephews, aunts, uncles, grandchildren, cousins, half-siblings) of T1D probands, ages 1 – 20 years.
Status: Institutional Review Board (IRB) approved.
For more information, please call Dr. Ying Chang at 717-531-4751.
Type 2 Diabetes Clinical Trial
This trial studies the effectiveness and safety of several diabetes medications in children age 10 to 16 years with Type 2 diabetes, specifically:
- Liraglutide in combination with metformin versus Metformin monotherapy on glycaemic control
This is a 26-week double-blind, randomized, parallel group, placebo controlled multi-centre trial followed by a 26-week open-label extension.
During the trial, children with Type 2 diabetes are randomly assigned into metformin therapy or metformin plus liraglutide. Liraglutide is a medicine belonging to glucagon like peptide-1 (GLP-1), which is a potent glucose lowering agent used for Type 2 diabetes treatment. Liraglutide is given via subcutaneous injection, once a day.
Status: Actively enrolling
For more information, please call Dr. Ying Chang at 717-531-4751.